Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zarate

Showing results (451-460 of 606) with videos related to

Pageof 61
Sort By:
JAMA Psychiatry|February 12, 2025
Making Progress in Clinical Trials for Suicide Prevention: A ReviewSamuel T Wilkinson, Craig J Bryan, Larry D Alphs, et al.
The American Journal of Psychiatry|July 2, 2003
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week studyMauricio Tohen, Terence A Ketter, Carlos A Zarate, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 3, 2012
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled studyLobna Ibrahim, Nancy Diazgranados, Jose Franco-Chaves, et al.
Journal of Affective Disorders|August 30, 2024
The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trialRodrigo Machado-Vieira, Gregory H Jones, Alan C Courtes, et al.
The International Journal of Neuropsychopharmacology|December 25, 2014
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorderMark J Niciu, David A Luckenbaugh, Dawn F Ionescu, et al.
Journal of Neuroendocrinology|January 20, 2026
Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate markerHiroe Hu, Yoojin Lee, Alaina N Tillman, et al.
Therapeutic Advances in Chronic Disease|May 9, 2015
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective reviewNicolas D Iadarola, Mark J Niciu, Erica M Richards, et al.
Biological Psychiatry|September 18, 2024
Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use DisordersAnna Onisiforou, Andria Michael, Markos Apostolakis, et al.
The American Journal of Psychiatry|May 15, 2012
A developmental study of the neural circuitry mediating motor inhibition in bipolar disorderJudah D Weathers, Argyris Stringaris, Christen M Deveney, et al.
The Journal of Clinical Psychiatry|June 24, 2016
Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar DisorderElizabeth D Ballard, Jennifer L Vande Voort, Rebecca A Bernert, et al.
Pageof 61

Showing results (451-460 of 606) with videos related to

Sort By:
Pageof 61
JAMA Psychiatry|February 12, 2025
Making Progress in Clinical Trials for Suicide Prevention: A ReviewSamuel T Wilkinson, Craig J Bryan, Larry D Alphs, et al.
The American Journal of Psychiatry|July 2, 2003
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week studyMauricio Tohen, Terence A Ketter, Carlos A Zarate, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 3, 2012
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled studyLobna Ibrahim, Nancy Diazgranados, Jose Franco-Chaves, et al.
Journal of Affective Disorders|August 30, 2024
The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trialRodrigo Machado-Vieira, Gregory H Jones, Alan C Courtes, et al.
The International Journal of Neuropsychopharmacology|December 25, 2014
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorderMark J Niciu, David A Luckenbaugh, Dawn F Ionescu, et al.
Journal of Neuroendocrinology|January 20, 2026
Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate markerHiroe Hu, Yoojin Lee, Alaina N Tillman, et al.
Therapeutic Advances in Chronic Disease|May 9, 2015
Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective reviewNicolas D Iadarola, Mark J Niciu, Erica M Richards, et al.
Biological Psychiatry|September 18, 2024
Ketamine and Hydroxynorketamine as Novel Pharmacotherapies for the Treatment of Opioid Use DisordersAnna Onisiforou, Andria Michael, Markos Apostolakis, et al.
The American Journal of Psychiatry|May 15, 2012
A developmental study of the neural circuitry mediating motor inhibition in bipolar disorderJudah D Weathers, Argyris Stringaris, Christen M Deveney, et al.
The Journal of Clinical Psychiatry|June 24, 2016
Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar DisorderElizabeth D Ballard, Jennifer L Vande Voort, Rebecca A Bernert, et al.
Pageof 61